Joint Effort by Health and Family Ministries to Develop Evidence-Based Guidelines for Gender Dysphoria in Adolescents

Schillaci and Roccella Collaborating on New guidelines for Triptorelin Dysphoria

The Ministry of Health and the Ministry of Family have come together to discuss the use of triptorelin, a puberty blocking drug, for gender dysphoria in minors. This collaborative effort is led by Ministers Orazio Schillaci and Eugenia Roccella, with a team of technicians and experts working to develop new guidelines based on scientific literature and experiences from other countries.

The two ministries released a joint statement summarizing the work done so far on gender dysphoria in adolescents, including a hearing with scientific societies and a request to the National Bioethics Committee to reevaluate the use of triptorelin in cases of dysphoria. In addition, they are conducting a survey among regions regarding clinical monitoring, expenditures, and prescriptions of triptorelin for cases of dysphoria, and have requested a report from AIFA on the therapeutic indications for the drug.

This proactive approach to addressing gender dysphoria in minors aims to provide evidence-based guidelines and best practices for healthcare providers working with this complex issue. Stay tuned for updates as the team continues its work to develop specific guidelines for this important issue.

Leave a Reply